Association of Glucose-Lowering Therapy with Myocardial Work Recovery and Reverse Remodeling After STEMI

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) patients with ST-segment elevation myocardial infarction (STEMI) face high risks of adverse cardiac remodeling post-reperfusion.
• Understanding the impact of pre-admission glucose-lowering therapies on cardiac recovery is crucial for this high-risk population.

Purpose of the Study:

• To investigate the association between pre-admission glucose-lowering therapy classes and six-month left ventricular (LV) reverse remodeling and myocardial work recovery in STEMI patients with T2DM.
• To compare the effects of SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and conventional therapy on cardiac outcomes.

Main Methods:

• Observational study analyzing 253 STEMI patients with baseline LV ejection fraction ≤ 50% and successful primary PCI.
• Primary analysis focused on 75 T2DM patients, categorized by pre-admission therapy (SGLT-2 inhibitors, GLP-1 RAs, DPP-4 inhibitors, conventional).
• Echocardiography assessed LV remodeling and myocardial work at baseline and six months; clinical outcomes were also analyzed.

Main Results:

• Pre-admission SGLT-2 inhibitor and GLP-1 receptor agonist use was linked to significantly greater improvements in LVEF, LV volumes, and global work efficiency compared to DPP-4 inhibitors or conventional therapy.
• Crude Major Adverse Cardiovascular Events (MACE) rates were highest in the conventional therapy group, though estimates were imprecise.
• These findings suggest a potential benefit of specific glucose-lowering agents in improving cardiac structure and function post-STEMI.

Conclusions:

• In T2DM patients recovering from STEMI, pre-admission use of SGLT-2 inhibitors and GLP-1 receptor agonists was associated with more favorable cardiac structural and myocardial work recovery.
• These hypothesis-generating results highlight potential therapeutic advantages of SGLT-2 inhibitors and GLP-1 RAs.
• Further confirmation in large prospective studies is warranted to validate these associations.